An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for treatment of central nervous system (CNS) progression post-radiotherapy in patients (pts) with HER2-positive metastatic breast cancer (MBC): PATRICIA.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nancy U. Lin, Catherine Lai, Andrea Lacasia, Alisha Stein, Bongin Yoo, Anita Fung, Mark D. Pegram
Institutions: Dana-Farber Cancer Institute, Genentech, Stanford Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2638009829